Table 1.
Number of samples sequenced from stool samples submitted at each visit
| Visit | Samples, na | Mean ± SD number of sequences called to family |
| Open-label baseline (V3) | 101 | 3,465,091 ± 2,469,103 |
| Open-label week 2 (V4) | 102b | 3,511,837 ± 2,496,318 |
| Double-blind baseline (V6) | 69 | 3,177,231 ± 2,158,671 |
| Double-blind week 2 (V7) | 72 | 4,199,975 ± 3,653,364 |
| End of study (V11) | 96 | 4,095,411 ± 2,361,115 |
A total of 103 patients with IBS-D were included in the study, but no patients had samples evaluated at all time points.
b
Individual patients could have had ≥ 1 sample evaluated at a given time point.
IBS-D: diarrhoea-predominant irritable bowel syndrome; SD: standard deviation; V: clinic visit